Double Extrusion Ocular Implant for Sustained Dexamethasone Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular conditions, such as macular degeneration and uveitis, face challenges with delivering therapeutic agents effectively to the posterior segment of the eye due to limited intraocular concentration and systemic side effects from conventional administration methods, including short drug half-lives and frequent injections that increase the risk of complications.
Innovation Solution
A bioerodible implant comprising a biodegradable polymer matrix with a therapeutic agent, specifically dexamethasone, is implanted in the vitreous to provide sustained release, bypassing blood-eye barriers and minimizing systemic toxicity, using a double extrusion process for uniform distribution and controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional administration methods are used to deliver therapeutic agents to the posterior segment of the eye, then the treatment can be administered, but the intraocular concentration is limited and systemic side effects occur
Solution Approach 1:
The invention divides the drug delivery system into separate compartments: a reservoir containing the therapeutic agent (dexamethasone) and a biodegradable polymer matrix. This segmentation allows the drug to be delivered directly to the posterior segment of the eye while preventing systemic distribution, thereby achieving high intraocular concentration without systemic side effects
Solution Approach 2:
The biodegradable polymer matrix acts as an intermediary carrier that transports the therapeutic agent from the reservoir to the target site in the posterior segment of the eye. This intermediary enables controlled local delivery while preventing the drug from entering the systemic circulation
2Duration of action of moving object
If conventional administration methods are used, then treatment can be provided, but the drug half-life is short requiring frequent injections
Solution Approach 1:
The invention incorporates a large reservoir of therapeutic agent within the biodegradable polymer matrix before implantation. This preliminary loading of the reservoir provides a sustained supply of drug that releases over an extended period (months), eliminating the need for frequent reinjections and extending the duration of action
Solution Approach 2:
The biodegradable polymer matrix provides continuous controlled release of the therapeutic agent from the reservoir over an extended period. This continuous action maintains therapeutic levels in the posterior segment of the eye without interruption, replacing the discontinuous administration required by conventional short-half-life drugs
3Reliability
If conventional administration methods are used, then treatment can be administered, but frequent injections increase the risk of complications
Solution Approach 1:
By segmenting the drug delivery into a implanted reservoir system that provides sustained release, the invention eliminates the need for repeated invasive injections. This single implantation event maintains treatment effectiveness over months while reducing cumulative procedural risks
Solution Approach 2:
The biodegradable polymer matrix with its embedded reservoir provides self-sustained drug delivery without requiring external intervention or repeated injections. The system automatically maintains therapeutic levels through controlled diffusion, reducing the frequency of medical procedures and associated complications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implant achieves prolonged therapeutic levels of dexamethasone in the vitreous humor with reduced side effects, maintaining effective drug concentrations for extended periods, thereby improving treatment outcomes for ocular conditions like macular edema and uveitis while minimizing systemic exposure.
Implementation Method 1
The implant is made by a double extrusion process... providing sustained release, bypassing blood-eye barriers
Implementation Method 2
bioerodible implant comprising an active agent and a bioerodible polymer matrix
Data Source
AI summary
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.